Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors-Reference-Cited by-同舟云学术

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors

Published:2020-08-27 Issue:12 Volume:28 Page:6129-6143
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Dougan Michael,Blidner Ada G.,Choi Jennifer,Cooksley Tim,Glezerman Ilya,Ginex Pamela,Girotra Monica,Gupta Dipti,Johnson Douglas,Shannon Vickie R.,Suarez-Almazor Maria,Anderson Ronald,Rapoport Bernardo L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-020-05707-3.pdf

Reference81 articles.

1. Dougan M (2017) Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol 8:1547. https://doi.org/10.3389/fimmu.2017.01547

2. Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G (2018) Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res 6(12):1453–1458. https://doi.org/10.1158/2326-6066.CIR-17-0659

3. Reynolds K, Thomas M, Dougan M (2018) Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 23(9):991–997. https://doi.org/10.1634/theoncologist.2018-0174

4. Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F (2019) Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA Adverse Event Reporting System. Target Oncol 14(2):205–221. https://doi.org/10.1007/s11523-019-00632-w

5. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y (2019) Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7(1):118. https://doi.org/10.1186/s40425-019-0604-2

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed-Onset Immune-Related Colitis Following Pancreaticoduodenectomy in Patients With Gastric Cancer and Pancreatic Invasion Treated With Immune Checkpoint Inhibitors;Cureus;2024-09-02

2. Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery;International Immunopharmacology;2024-08

3. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

4. CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events;Holistic Integrative Oncology;2024-06-28

5. Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors;Anais Brasileiros de Dermatologia;2024-05